Pharmaceuticals, Biotechnology and Life Sciences
The approval of the AC-170 NDA after December 1, 2016 would trigger a milestone payment of $10 million in Nicox shares to ex-Aciex shareholders or $35 million in Nicox shares if approval of the NDA is received before this date.
ABIVAX is hosting an R&D Day at the Company’s new collaborative laboratory with the French National Center for Scientific Research (CNRS) in Montpellier.
Biocartis Group NV, a Belgian innovative molecular diagnostics company has published a comparative study organised by AstraZeneca where 12 different KRAS mutation detecting technologies, including Next-Generation Sequencing (NGS) and quantitative Polymerase Chain Reaction (PCR), were compared for the detection of KRAS mutations in lung cancer, using blinded samples.
Oxford BioMedica, a UK-based gene and cell therapy group, has published results from the RetinoStat (OXB-201) Phase I study in patients with advanced wet age-related macular degeneration (AMD) in the journal Human Gene Therapy.
Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell…
Novartis has announced today that results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended…
Verona Pharma #VRP appoints Vikas Sinha to the Board as a Non-Executive Director
David Evans, Non-executive Chairman, has stepped down from the Board with immediate effect.
Quay Pharma will be formulating the capsules that will be administered in Redx’s trial.
“Second quarter financial performance was in-line with expectations.” – Olivier Brandicourt, Sanofi CEO